RT Journal Article
SR Electronic
T1 Monoclonal antibodies for treating COVID-19
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
DO 10.3949/ccjm.88a.ccc074
A1 Andrea M. Pallotta
A1 ChungYun Kim
A1 Steven M. Gordon
A1 Alice Kim
YR 2021
UL http://www.ccjm.org/content/early/2021/02/17/ccjm.88a.ccc074.abstract
AB Bamlanivimab and casirivimab-imdevimab are novel virus-neutralizing monoclonal antibodies authorized to treat mild to moderate COVID-19 in outpatients at risk for progression to severe disease. Treatment early in the disease may show efficacy in reducing progression to severe disease, although safety and efficacy data are limited. They are not authorized for hospitalized patients with more advanced disease.